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In the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease worldwide,
primarily as a result of the epidemic of obesity. NAFLD is strongly associated with insulin resistance, glucose intolerance, and
dyslipidemia and is currently regarded as the liver manifestation of the metabolic syndrome, a highly atherogenic condition even
at a very early age. Patients with NAFLD including pediatric subjects have a higher prevalence of subclinical atherosclerosis, as
shown by impaired flow-mediated vasodilation, increased carotid artery intima-media thickness, and arterial stiffness, which are
independent of obesity and other established risk factors. More recent work has identified NAFLD as a risk factor not only for
premature coronary heart disease and cardiovascular events, but also for early subclinical abnormalities in myocardial structure
and function. Thus, we conducted a systematic review and meta-analysis to test the hypothesis that NAFLD is associated with
evidence of subclinical cardiac structural and functional abnormalities.
1. Introduction
In the last 20 years, nonalcoholic fatty liver disease (NAFLD)
has become the leading cause of chronic liver disease world-
wide, primarily as a result of the epidemic of obesity [1–
4]. NAFLD is a spectrum of fat-associated liver conditions
that can result in end-stage liver disease and the need for
liver transplantation [5–7]. Simple steatosis, or fatty liver,
occurs early in NAFLD and may progress to nonalcoholic
steatohepatitis (NASH), fibrosis, and cirrhosis with increased
risk of hepatocellular carcinoma [5–7]. NAFLD is strongly
associated with obesity, insulin resistance, hypertension, and
dyslipidemia and is now regarded as the livermanifestation of
the metabolic syndrome (MetS) [8–10], a highly atherogenic
condition even at a very early age [11–13]. When compared to
control subjects who do not have hepatic steatosis, patients
with NAFLD have a higher prevalence of atherosclerosis, as
shown by increased carotid wall intimal thickness, increased
numbers of atherosclerotic plaques, and increased plasma
markers of endothelial dysfunction,which are independent of
obesity and other established risk factors [13–19]. Consistent
with these observations, natural history studies have reported
that the increased age-related mortality observed in patients
with NAFLD is attributable to cardiovascular as well as
liver-related deaths [11, 20]. More recent work has identified
NAFLDas a risk factor also for early subclinical abnormalities
in myocardial metabolism as well as in cardiac structure
and function [21–29]. In particular, it has been shown that
NAFLD is associated with myocardial insulin resistance,
altered cardiac energy metabolism, left ventricular (LV)
hypertrophy, and impaired diastolic function [23–29]. How-
ever, a comprehensive evaluation of the impact of NAFLD
on these complications is lacking. Thus, we conducted a
systematic review and meta-analysis to test the hypothesis
that NAFLD is associated with evidence of subclinical cardiac
structural and functional abnormalities.
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2. Methods
2.1. Search Strategy. A systematic literature search was con-
ducted by two researchers (LP and CA) to identify all
articles (published from January 2000 to September 2014)
that assessed by echocardiography cardiac geometry and
function in NAFLD patients. We performed the search in
Medline, EMBASE, and the Cochrane Library. Search terms
were NAFLD OR NASH OR nonalcoholic fatty liver disease
OR nonalcoholic steatohepatitis OR fatty liver OR liver fat
OR steatosis OR liver enzymes OR transaminase ORALTOR
AST OR GGT OR severity of liver disease AND left ventricle
OR left ventricular hypertrophy OR cardiac hypertrophy
OR cardiac dysfunction OR ventricular dysfunction OR
echocardiography. Search results were limited to English
language publications. References of included articles were
manually searched for other relevant studies.
2.2. Study Selection. Inclusion criteria were observational
studies including quantitative data on LV structure and/or
function assessed by echocardiography and NAFLD diag-
nosed by (1) liver histology, (2) imaging (ultrasound, com-
puted tomography, magnetic resonance imaging (MRI), or
spectroscopy (MRS)), or (3) biochemistry (elevations in
serum aspartate aminotransferase, alanine aminotransferase
(ALT), or gamma-glutamyl transferase). Competing causes of
steatosis, including alcohol consumption and viral, autoim-
mune, and metabolic hepatitis, had to be excluded. Only
the updated or largest report was considered when multiple
publications by the same research group were found.
2.3. Data Extraction andQuality Assessment. Data extraction
was performed independently by two authors (EB and LP)
and included title, authors, date of publication, study design,
inclusion and exclusion criteria used in the study, number of
patients and controls, the diagnostic procedures for NAFLD,
the echocardiographic methods, and LV structural and func-
tional measures. All quantitative echocardiographic variables
had to be expressed as means ± SD; otherwise SE or 95%
confidence intervals (CI) were used to estimate the SD.
The quality of the selected studies was assessed indepen-
dently by two authors (EB and CC) using the Newcastle-
Ottawa Scale (NOS) for cohort and cross-sectional studies.
The NOS uses a “star” rating system to judge quality based
on three aspects of the study: selection of study groups,
comparability of study groups, and ascertainment of either
the exposure or outcome of interest [36]. Any discrepancies
were addressed by a joint reevaluation of the original article
with another author.
2.4. Statistical Analysis. We calculated effect size for the
following measures of LV structure and function: LV mass
index, early mitral velocity (𝐸)/late mitral velocity (𝐴) ratio,
and 𝐸/early diastolic tissue velocity (𝑒󸀠) ratio. We used
the standardized difference, which is the mean difference
(between cases and controls) divided by the commonwithin-
group standard deviation for cardiac parameters. We chose
the standardized mean difference as a measure of association
instead of the weighted mean difference since the outcome
variables had been determined by different instruments.
Fixed or random-effect models were used to summarize
results. The standardized differences were evaluated using
the Der-Simonian and Laird procedures. In this analysis,
the variation among studies is incorporated and thus the
overall outcome estimates have greater standard errors. The
Der-Simonian and Laird method uses weights equal to the
reciprocal of the variance of the individual outcome estimates
and thus takes account of the variation between them.
Heterogeneitywas estimated using the 𝐼2 index. If the 𝐼2 value
was <50%, a fixed-effect meta-analysis was applied. If the 𝐼2
value was ≥50%, a random-effect meta-analysis was used.
We used Cohen’s categories to evaluate the magnitude of
the effect size, calculated by the standardizedmeandifference,
where 𝑑 of 0.2–0.5 indicates a small effect size, 𝑑 > 0.5–0.8
indicates a medium effect size, and 𝑑 > 0.8 indicates a large
effect size [37].
Publication bias was checked visually by creating a fun-
nel plot with the standard error plotted against the mean
difference of single LV parameters. In addition, publication
bias was statistically tested by Egger’s test. Consistent with
recommendations to determine stability in the meta-analytic
results, we computed the classic fail-safe𝑁 analysis [38].This
technique calculates the number of studies with nonsignifi-
cant effects required to nullify the overall effect determined
in the current analysis. Larger fail-safe 𝑁 values increase
confidence in the overall effect and validate the stability of
the current findings. Data were analyzed with the use of the
Comprehensive Meta-Analysis software, version 2 (Biostat,
Englewood, New Jersey).
3. Results
3.1. Characteristics of the Studies. The first literature search
identified 461 papers; 22 of these were potentially eligible
for the analysis, but only 9 studies, six involving adults
[25, 26, 30–33] and three with children and adolescents [29,
34, 35], could be included in the final review (Figure 1).
Overall themethodological quality of the selected studies was
satisfactory.
3.1.1. Adult Studies. Table 1(a) summarizes the studies on
the effects of NAFLD on cardiac structure and function in
adults. Overall, 629 adult patients with NAFLD and 1237
controls were included in the studies. Control subjects were
matched for age and sex in some studies and for age, sex,
and body mass index (BMI) or for age, sex, BMI, and waist
circumference in others. Five studies were hospital-based
case-control ones [25, 26, 30–32], and one was a population-
based cross-sectional survey [33]. In all cases and controls,
LV geometry and function was measured by M-mode and
pulsed Doppler echocardiography; tissue Doppler imaging
(TDI) was also used in the majority of studies (5 of the 6
studies) (Table 1).
NAFLD was defined by liver histology in one study, by
ultrasound in four studies, and by computed tomography
scan in one study. Three studies enrolled exclusively non-
diabetic, normotensive individuals, one study enrolled type
2 diabetic patients, and one study enrolled never-treated
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Studies identified and 
Appropriate studies to be
included in the review
Studies included
in the final review
Studies excluded based on 
title and abstract review
screened for retrieval
(n = 439)
(n = 22)
(n = 9)
(ii) Double or serial publications (n = 1)
(iii) Lack of minimal set of clinical data (n = 2)
(iv) Miscellaneous reasons (n = 4)
(i) No echocardiographic data in controls (n = 6)
(n = 461)
Figure 1: Schematic flow chart for the selection of studies.
Study name
Statistics for each study
Std. diff. in means and 95% CI
Goland et al. 2006
Fotbolcu et al. 2010
Bonapace et al. 2012
Karabay et al. 2014
Std. diff.
in means
0.485
1.661
0.284
0.903
0.835
Standard 
error
0.261
0.288
0.296
0.267
0.295
Variance
0.068
0.083
0.088
0.071
0.087
Upper
limit
0.996
2.226
0.864
1.426
1.409
0.00 2.00 4.00
Overall
(random)
NAFLD NO NAFLD
−4.00 −2.00
Lower
limit
1.096
0.380
0.254
−0.027
−0.296
0.063
0.000
0.337
0.001
0.005
1.856
5.761
0.960
3.384
2.826
Z-value
Heterogeneity: Q-value 13.5 df(Q) 3 (P < 0.004) I2 = 77.8%
P value
Figure 2: Forest plots show the comparison of LV mass indexed to BSA between NAFLD patients and NO NAFLD subjects.
essential hypertensive patients. The population-based study
included patients with NAFLD and MetS.
3.1.2. Pediatric Studies. Table 1(b) summarizes the studies
on the effects of NAFLD on cardiac structure and function
in children and adolescents [29, 34, 35]. Overall, 244 obese
children with NAFLD, 680 obese subjects without liver
involvement, and 236 healthy controls matched for age and
gender were included in the studies. In all cases and controls,
LV geometry and function wasmeasured byM-mode, pulsed
Doppler, and TDI.
NAFLD was defined by ultrasound in one study, by
ultrasound and elevated serumALT in one study, and byMRI
(and liver biopsy in a subgroup) in one study.
3.2. Cardiac Parameters. The parameters reported across the
selected publications varied among studies, but LV mass
indexed to height2.7 or to body surface area (BSA), 𝐸/𝐴 ratio,
the early annular diastolic tissue velocity (𝑒󸀠), and 𝐸/𝑒󸀠 ratio
were the most frequently reported outcomes.
3.2.1. Adult Studies. Two studies reported LVmass indexed to
height2.7 [30, 33] and 4 studies the LV mass indexed to BSA
[25, 26, 31, 32]. Four studies found an increased LVmass index
in NAFLD patients compared to controls. When pooling the
data on LV mass indexed to height2.7 as well as those on LV
mass indexed to BSA, the standardized difference in means
was statistically significant (𝑃 < 0.0001) only for LV mass
indexed to BSA (Figure 2). There was significant evidence
of heterogeneity among the studies. 𝐸/𝐴 ratio was available
in all 6 studies. On average, a worse 𝐸/𝐴 ratio was found
in NAFLD patients, with a standardized mean difference of
−0.57 (95% CI, −0.67 to −0.47; 𝑃 < 0.0001) (Figure 3). 𝐸/𝑒󸀠
ratio was reported in 5 of the 6 studies. Patients with NAFLD
had higher 𝐸/𝑒󸀠 ratio than those without NAFLD in 4 of the
5 studies, leading to a standardized mean difference of 0.56
(95% CI, 0.45 to 0.66; 𝑃 < 0.0001) (Figure 4). Again, there
was heterogeneity among studies.
We found no evidence of publication bias based on
Egger’s test with respect to 𝐸/𝐴 ratio (intercept = −0.55 (95%
CI, −4.55 to 3.46); 𝑃 = 0.72) and 𝐸/𝑒󸀠 ratio (intercept = 1.95
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Karabay et al. 2014
P value
Figure 3: Forest plots show the comparison of earlymitral velocity (𝐸)/latemitral velocity (𝐴) ratio betweenNAFLDpatients andNONAFLD
subjects.
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Figure 4: Forest plots show the comparison of 𝐸/early diastolic tissue velocity (𝑒󸀠) ratio between NAFLD patients and NO NAFLD subjects.
(95% CI, −5.01 to 8.90); 𝑃 = 0.44). The classic fail-safe𝑁 was
relatively high to lower the significance of this meta-analysis
(number of missing studies that would make 𝑃 value greater
than alpha = 120).
3.2.2. Pediatric Studies. When pooling the data on LV mass
indexed to height2.7, the standardized mean difference in
LV mass between obese children with NAFLD and obese
subjects without liver involvement did not reach statistical
significance (𝑃 = 0.069). In contrast, when compared to
healthy lean controls, the standardizedmean difference in LV
mass was statistically significant (mean, 1.19 (95% CI, 0.99 to
1.39); 𝑃 < 0.0001) (Figure 5). In all studies, no significant
differences were found in 𝐸/𝐴 ratio between the groups
(Figure 6). However, obese children and adolescents with
NAFLD had higher 𝐸/𝑒󸀠 ratio than those without NAFLD,
leading to a standardized mean difference of 0.31 (95% CI,
0.11 to 0.51; 𝑃 < 0.001) (Figure 7). In contrast to adult
population, there was no evidence of heterogeneity among
pediatric studies. We found no evidence of publication bias
based on Egger’s test with respect to 𝐸/𝐴 ratio (intercept =
−1.41 (95% CI, −4.46 to 3.76); 𝑃 = 0.72). Visual inspection
of the funnel plot suggested the absence of publication bias
for the 𝐸/𝑒󸀠 ratio, which was identified in 2 of the 3 eligible
studies. However, the classic fail-safe 𝑁 was relatively low
when considering obese children with and without NAFLD,
suggesting that only tenuous conclusions should be drawn.
4. Discussion
While previous systematic reviews and meta-analyses have
investigated the association between NAFLD and the risk of
cardiovascular events (such as myocardial infarction, angina
pectoris, and ischemic stroke), cerebrovascular disease (such
as cerebral hemorrhage), and peripheral vascular disease
[39], or the effect of current treatments onNAFLD-associated
cardiometabolic conditions [40], in the present systematic
review and meta-analysis, the association of subclinical car-
diac structure and function abnormalities in patients with
NAFLD has been examined.
We found that NAFLD patients both adults and children
have increased features of diastolic LV dysfunction. In fact,
NAFLD adult patients had a lower 𝐸/𝐴 ratio and a higher
𝐸/𝑒
󸀠 ratio, while children with NAFLD had higher 𝐸/𝑒󸀠 ratio.
Diastolic LV dysfunction is increasingly acknowledged as
a major contributor to the development of heart failure, but
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(b)
Figure 5: Forest plots show the comparison of LVmass indexed to height2.7 betweenNAFLD andNONAFLD obese children and adolescents
(a) and between obese children with NAFLD and healthy lean subjects (b).
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Figure 6: Forest plots show the comparison of early mitral velocity (𝐸)/late mitral velocity (𝐴) ratio between NAFLD and NONAFLD obese
children and adolescents.
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Figure 7: Forest plots show the comparison of 𝐸/early diastolic tissue velocity (𝑒󸀠) ratio between NAFLD and NO NAFLD obese children
and adolescents.
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as the early onset of heart failure with preserved systolic func-
tion (e.g., preclinical diastolic dysfunction) is asymptomatic,
it is often not diagnosed in the early stages [41]. Although
systolic function is well characterized by determinations of
ejection fraction, diastolic function characterization of the
heart’s stiffness, relaxation, and pressure changes is more
difficult. Invasive measures of rate of LV pressure decline, LV
relaxation time constant, and stiffness modulus can charac-
terize diastolic function [42]. Echocardiography, a common
noninvasive imaging technique, is useful in determining the
presence of systolic or diastolic dysfunction. In the diastole,
the LV filling pattern consists of 2 phases: early and late
atrial contraction. The 𝐸/𝐴 ratio is used as an estimate of
the relaxation pattern of the ventricle. Furthermore, TDI can
be used to measure myocardial motion, specifically the rate
at which the mitral annulus moves toward the base during
early diastole (𝑒󸀠).TheLVfilling pressures can be estimated by
the 𝐸/𝑒󸀠 ratio [42]. Thus 𝐸/𝐴 ratio and 𝐸/𝑒󸀠 ratio are reliable
markers of LV diastolic function.
In addition to LVdiastolic dysfunction, ourmeta-analysis
showed significant differences in LV mass index, a contin-
uous measure of cardiac structure, between adult patients
with NAFLD and controls. In the pediatric population, the
standardized mean difference in LV mass between obese
children with NAFLD and obese subjects without liver
involvement did not reach statistical significance. However,
when compared to healthy lean controls, the standardized
mean difference in LV mass was statistically significant.
Although LV diastolic dysfunction is known to be associated
with the development of LV hypertrophy, investigations in
both human and animal models of hypertension suggest that
early LV diastolic dysfunction may precede the development
of LV hypertrophy [43].
It should be pointed out that, in a meta-analysis, the
presence of heterogeneity in study design and clinical char-
acteristics of subjects may influence the interpretation of
the pooled risk estimates. However, even using the random-
effects model, taking account of the variation between the
different studies yielded a statistically significant estimate of
LV dysfunction. Of note, there was no evidence of statisti-
cally significant heterogeneity among the studies involving
children.
The severity of liver disease was not considered inmost of
the studies.Thismay be due to liver biopsy being invasive and
expensive and the ever present possibility of complications.
Only one study in adults and one in children disclosed cardiac
data according to liver histology and showed conflicting
results. Karabay et al. [32] found no significant differences
in cardiac dysfunction among NAFLD groups (e.g., simple
steatosis, borderline NASH, and definite NASH). In contrast,
Pacifico et al. [29] showed that obese children with NAFLD
have features of early LV dysfunction, compared to obese
children without NAFLD and lean controls. Notably, when
the group of obese subjects was divided according to the pres-
ence of NASH, it was evident that some functional cardiac
differences were more pronounced in the group of NASH.
Therefore, some misclassification of individuals with NASH
as controls would probably tend to reduce the strength of
the association between NAFLD and cardiac abnormalities.
Interpretation of the results of this meta-analysis is limited
by other caveats; that is, a small number of studies met the
inclusion criteria, and all the reported analyses relied on the
standardizedmean differences between patients and controls,
without adjustment for other potential confounder factors.
Although the pathogenesis of cardiac dysfunction in
NAFLD is still unclear, insulin resistance, abnormal lipid
profile, and low-grade inflammatory state have been sug-
gested to play a role [44–47]. Hepatic steatosis is associated
with hepatic insulin resistance, which means that hepatic
glucose production is impaired, leading to hyperglycemia
and compensatory hyperinsulinemia. This may worsen both
systemic and cardiac insulin resistance. The liver plays an
important role in controlling the amount of circulating lipids.
In patients with NAFLD, the increase in free fatty acids
may lead to myocardial lipid accumulation, with consequent
alterations in LV function [46–48]. In fact, myocardial steato-
sis may cause changes in myocardial substrate metabolism
and efficiency (as measured by cardiac work/myocardial
oxygen consumption) that occur early in the process lead-
ing to impaired LV contractility [44, 45]. Using 1H-MRS,
Rijzewijk et al. showed that the intramyocardial fat content
was significantly higher in uncomplicated type 2 diabeticmen
than in nondiabetic controls and was related to impaired car-
diac metabolism [49]. Epicardial adipose tissue (EAT), being
metabolically active, produces proatherogenic, proinflamma-
tory, and prothrombotic adipocytokines [50, 51]. Its anatomic
location, without any barrier to the adjacent myocardium,
results in local paracrine interaction between EAT and the
myocardium [52]. Perseghin et al. who used cardiacMRI and
31P-MRS showed that patients with fatty liver had increased
epicardial fat and abnormal cardiac metabolism [24]. Thus,
epicardial and myocardial fat represent abnormal ectopic fat
storage and may be a marker of the cumulative effects of
NAFLD and insulin resistance in the setting of pathological
adiposity [48, 52], leading to cardiovascular complications
[53].
More recently, it has been shown that the liver activates
homeostatic mechanisms which increase the production and
export of non-HDL-C to reduce the toxic effect of excess
cholesterol due to diet. Thus, the liver may limit free choles-
terol toxicity, but a consequence is that APOB-containing
atherogenic lipoproteins are produced, which may, at least
in part, account for the increased cardiovascular risk in
patients with NAFLD [54]. Emerging evidence also suggests
that NAFLD, especially in its necroinflammatory form,might
be involved in the pathogenesis of cardiac function abnor-
malities through the systemic release of several mediators
from the steatotic and inflamed liver (including C-reactive
protein, interleukin-6, tumor necrosis factor-𝛼, and other
proinflammatory cytokines) [11, 55].
Genetic studies have highlighted several single nucleotide
polymorphisms that may characterize patients with a high
risk for NAFLD development and progression [56–60]. In
particular, a common missense variant, rs738409 (I148M),
in the patatin-like phospholipase 3 (PNPLA3) gene has
been associated not only with increased hepatic fat content
and serum liver enzymes but also with increased risk of
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NASH and fibrosis progression [56, 58]. Recently, genetic
variation in the transmembrane 6 superfamily member 2
protein (TM6SF2) at rs58542926 has been shown to confer
susceptibility to NAFLD, independent of genetic variation in
PNPLA3 at rs738409 [59, 60]. Of note, the E167K variant
in TM6SF2 is associated with a distinct subtype of NAFLD,
characterized by preserved insulin sensitivity with regard
to lipolysis, hepatic glucose production, and lack of hyper-
triglyceridemia despite a clearly increased liver fat content
[61]. In addition, Dongiovanni et al. [62] found that the
TM6SF2 E167K variant increases susceptibility to NASH
and liver fibrosis but protects against cardiovascular disease
(CVD). Their findings suggest that inhibition of secretion of
very-low-density lipoproteins from the liver protects against
CVD, but at the cost of an increased risk of severe liver
disease.
In conclusion, our analysis supports the association
between NAFLD and subclinical cardiovascular changes.
However, confirmation in large cross-sectional and less het-
erogeneous studies is needed. If LV dysfunction in NAFLD is
confirmed, future research directions should include strate-
gies and interventions to prevent cardiac disease progression
in patients with NAFLD.
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